Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | Exploring the cognitive impact of BACE1 inhibition for Alzheimer’s disease

Robert Vassar • 8 Mar 2024
AD/PD 2024
Alzheimer’s Disease Dementia
AMARANTH DAYBREAK-ALZ

Robert Vassar, PhD, Feinberg School of Medicine, Northwestern University, Chicago, IL, summarizes the adverse impact on cognition elicited by β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) inhibition in patients with Alzheimer’s dementia during Phase III trials. As BACE1 cleaves many cellular substrates other than APP, Dr Vassar highlights that the inhibition of cleavage of an alternative substrate may be responsible for the cognitive worsening. Additionally, BACE1 inhibition unexpectedly resulted in patients experiencing disruption to sleep, insomnia, and vivid dreams, which may have impacted cognition. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Robert Vassar

Mechanistic insights into the connection between amyloid-beta and tau in Alzheimer's disease
3:14
Mechanistic insights into the connection between amyloid-beta and tau in Alzheimer's disease
Robert Vassar • 20 Mar 2026
Should amyloid and tau pathology be targeted together to treat Alzheimer's disease?
2:21
Should amyloid and tau pathology be targeted together to treat Alzheimer's disease?
Robert Vassar • 20 Mar 2026
Microglial cells in AD: their role in amyloid clearance and facilitating treatment effects
2:29
Microglial cells in AD: their role in amyloid clearance and facilitating treatment effects
Robert Vassar • 20 Mar 2026
Next steps in anti-amyloid immunotherapy
1:46
Next steps in anti-amyloid immunotherapy
Robert Vassar • 8 Mar 2024

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals